Intrapleural Urokinase for Retained Hemothorax

• Status: Unknown status
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Intrapleural thrombolytic treatment with urokinase for retained hemothorax is effective and safe. However, previous study was limited in prospective observation study without control group.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital

Criteria

Inclusion Criteria:

1. Retained hemothorax: it is defined as chest X-ray revealing obvious blood clot in pleural cavity after tube thoracostomy drainage for 3 days. The chest tubes are in good location and have no obstruction. The physician thinks the blood clot is difficult to drain.

2. Age: full 18 year-old

Exclusion Criteria:

1. Pregnancy

2. Active bleeding

3. Coagulopathy, e.g. congenital or acquired coagulation abnormality, platelet count less than 100,000 /μL, international normalized ratio (INR) more than 1.5, or partial thromboplastin time, PTT, more than 50 seconds after treatment.

4. Cerebrovascular accident within 30 days

5. History of intracranial tumor or vascular abnormality

6. Have received thoracic surgery

7. Have received pleurodesis

8. Wish to receive thoracoscopic surgery for hematoma evacuation directly

9. Allergy to urokinase

10. Sepsis

11. Shock

12. People who are less than 18 years of age, prisoners, aborigines.